Composite MRI scores improve correlation with EDSS in multiple sclerosis

Multiple Sclerosis

Volumn 16, Issue 9, 2010, Pages 1117-1125

  Poonawalla, A H ^a,b   Datta, S ^a   Juneja, V ^a   Nelson, F ^a   Wolinsky, J S ^a   Cutter, G ^c   Narayana, P A ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Biomarkers; composite score; EDSS; MRI; multiple sclerosis

Indexed keywords

GADOLINIUM;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CONTRAST ENHANCEMENT; EXPANDED DISABILITY STATUS SCALE; FEMALE; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RELAPSE; REMISSION; WHITE MATTER;

ADULT; CONTRAST MEDIA; CROSS-SECTIONAL STUDIES; DISABILITY EVALUATION; FEMALE; GADOLINIUM; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TEXAS;

EID: 77956320902     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510374892     Document Type: Article

References (55)

1. Kurtzke JF A new scale for evaluating disability in multiple sclerosis. Neurology 1955 ; 5: 580-583.
2. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983 ; 33: 1444-1452.
3. Miller DH and Thompson AJ Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis. Philos Trans R Soc Lond B Biol Sci 1999 ; 354: 1687-1695.
4. Wolinsky JS, Narayana PA, Noseworthy JH, Lublin FD, Whitaker JN, Linde A., Gjörstrup P. and Sullivan HC Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology 2000 ; 54: 1734-1741.
5. McFarland HF, Barkhof F., Antel J. and Miller DH The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult Scler 2002 ; 8: 40-51.
6. Li DK, Li MJ, Traboulsee A., Zhao G., Riddehough A. and Paty D. The use of MRI as an outcome measure in clinical trials. Adv Neurol 2006 ; 98: 203-226.
7. Erickson BJ and Noseworthy JH Value of magnetic resonance imaging in assessing efficacy in clinical trials of multiple sclerosis therapies. Mayo Clin Proc 1997 ; 72: 1080-1089.
8. Comi G. and Filippi M. Clinical trials in multiple sclerosis: methodological issues. Curr Opin Neurol 2005 ; 18: 245-252.
9. Bar-Zohar D., Agosta F., Goldstaub D. and Filippi M. Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives. Mult Scler 2008 ; 14: 719-727.
10. Zivadinov R. Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Neurology 2007 ; 68 (22 Suppl 3). S72 - S82. (discussion S91 - S96.
11. Zivadinov R. and Leist TP Clinical-magnetic resonance imaging correlations in multiple sclerosis. J Neuroimaging 2005 ; 15 (4 Suppl). 10S - 21S.
12. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002 ; 15: 239-245.
13. Barkhof F. MRI in multiple sclerosis: correlation with Expanded Disability Status Scale (EDSS). Mult Scler 1999 ; 5: 283-286.
14. Goodin DS Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment? Ann Neurol 2006 ; 59: 597-605.
15. Pulizzi A., Rovaris M., Judica E., Sormani MP, Martinelli V., Comi G. and Filippi M. Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study. Arch Neurol 2007 ; 64: 1163-1168.
16. Benedict RH, Bruce J., Dwyer MG, Weinstock-Guttman B., Tjoa C., Tavazzi E., Munschauer FE and Zivadinov R. Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Mult Scler 2007 ; 13: 722-730.
17. Tavazzi E., Dwyer MG, Weinstock-Guttman B., Lema J., Bastianello S., Bergamaschi R., Cosi V., Benedict RH, Munschauer FE 3rd and Zivadinov R. Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. Neuroimage 2007 ; 36: 746-754.
18. Sormani MP, Bruzzi P., Comi G. and Filippi M. MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. Neurology 2002 ; 58: 417-421.
19. Rudick RA, Lee JC, Simon J. and Fisher E. Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study. Ann Neurol 2006 ; 60: 236-242.
20. Kalkers NF, Bergers L., de Groot V., Lazeron RH, van Walderveen MA, Uitdehaag BM, Polman CH and Barkhof F. Concurrent validity of the MS Functional Composite using MRI as a biological disease marker. Neurology 2001 ; 56: 215-219.
21. Kalkers NF, Bergers E., Castelijns JA, van Walderveen MA, Bot JC, Adér HJ, Polman CH and Barkhof F. Optimizing the association between disability and biological markers in MS. Neurology 2001 ; 57: 1253-1258.
22. Neema M., Stankiewicz J., Arora A., Guss ZD and Bakshi R. MRI in multiple sclerosis: what's inside the toolbox?. Neurotherapeutics 2007 ; 4: 602-617.
23. Martinelli Boneschi F., Rovaris M., Comi G. and Filippi M. The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials. Mult Scler 2004 ; 10: 341-347.
24. Wolinsky JS, Narayana PA and Johnson KP United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. Mult Scler 2001 ; 7: 33-41.
25. Weisstein EW 'z-Score' http://mathworld.wolfram.com/z-Score.html ( 1999, accessed 10/24/2008).
26. Wolinsky JS, Narayana PA, Johnson KP, et al. The z4 score appears to have a predictive correlation as well that suggests that it might have the potential as a surrogate outcome measure. San Diego, CA: American Academy of Neurology, 2006.
27. Riahi F., Zijdenbos A., Narayanan S., Arnold D., Francis G., Antel J. and Evans AC Improved correlation between scores on the expanded disability status scale and cerebral lesion load in relapsing-remitting multiple sclerosis. Results of the application of new imaging methods. Brain 1998 ; 121: 1305-1312.
28. Duncan JS, Bartlett P. and Barker GJ Technique for measuring hippocampal T2 relaxation time. AJNR Am J Neuroradiol 1996 ; 17: 1805-1810.
29. Hoque R., Ledbetter C., Gonzalez-Toledo E., Misra V., Menon U., Kenner M., Rabinstein AA, Kelley RE, Zivadinov R. and Minagar A. The role of quantitative neuroimaging indices in the differentiation of ischemia from demyelination: an analytical study with case presentation. Int Rev Neurobiol 2007 ; 79: 491-519.
30. Neema M., Stankiewicz J., Arora A., Dandamudi VS, Batt CE, Guss ZD, Al-Sabbagh A and Bakshi R. T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis. J Neuroimaging 2007 ; 17 (Suppl 1). 16S - 21S.
31. Barbosa S., Blumhardt LD, Roberts N., Lock T. and Edwards RH Magnetic resonance relaxation time mapping in multiple sclerosis: normal appearing white matter and the 'invisible' lesion load. Magn Reson Imaging 1994 ; 12: 33-42.
32. Stevenson VL, Parker GJ, Barker GJ, Birnie K., Tofts PS, Miller DH and Thompson AJ Variations in T1 and T2 relaxation times of normal appearing white matter and lesions in multiple sclerosis. J Neurol Sci 2000 ; 178: 81-87.
33. http://www.fil.ion.ucl.ac.uk/spm/software/spm2/.
34. Sajja B., Datta S., He R. and Narayana P. Unified approach for multiple sclerosis lesion segmentation on brain MRI. Ann Biomed Eng 2006 ; 34: 142-151.
35. Datta S., Sajja BR, He R., Wolinsky JS, Gupta RK and Narayana PA Segmentation and quantification of black holes in multiple sclerosis. Neuroimage 2006 ; 29: 467-474.
36. Parry A., et al. White matter and lesion T1 relaxation times increase in parallel and correlate with disability in multiple sclerosis. J Neurol 2002 ; 249: 1279-1286.
37. Hasan KM, Gupta RK, Santos RM, Wolinsky JS and Narayana PA Diffusion tensor fractional anisotropy of the normal-appearing seven segments of the corpus callosum in healthy adults and relapsing-remitting multiple sclerosis patients. J Magn Reson Imaging 2005 ; 21: 735-743.
38. Vrenken H., Pouwels PJ, Ropele S., Knol DL, Geurts JJ, Polman CH, Barkhof F. and Castelijns JA Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease. Mult Scler 2007 ; 13: 708-716.
39. Bellmann-Strobl J., Stiepani H., Wuerfel J., Bohner G., Paul F., Warmuth C., Aktas O., Wandinger KP, Zipp F. and Klingebiel R. MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study. Eur Radiol 2009 ; 19: 2066-2074.
40. Narayana PA Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging 2005 ; 15 (4 Suppl). 46S - 57S.
41. Rashid W., Davies GR, Chard DT, Griffin CM, Altmann DR, Gordon R., Thompson AJ and Miller DH Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study. J Neurol Neurosurg Psychiatry 2006 ; 77: 51-55.
42. Nelson F., Poonawalla AH, Hou P., Huang F., Wolinsky JS and Narayana PA Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging. AJNR Am J Neuroradiol 2007 ; 28: 1645-1649.
43. Poonawalla AH, Datta S., Juneja V., Nelson F., Wolinsky JS, Cutter G. and Narayana PA Inverse dependence between patient population and correlation of composite MRI scores with EDSS in Multiple Sclerosis. Proc. 17th Scientific Meeting of ISMRM at Hawaii, USA, April 2009 ; Abstract #1149 2009; 17.
44. Fisher E. Rudick RA, Simon JH, Cutter G., Baier M., Lee JC, Miller D., Weinstock-Guttman B., Mass MK, Dougherty DS and Simonian NA Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002 ; 59: 1412-1420.
45. Kappos L., Moeri D., Radue EW, Schoetzau A., Schweikert K., Barkhof F., Miller D., Guttmann CR, Weiner HL, Gasperini C. and Filippi M. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999 ; 353: 964.
46. Paty DW and Li DK Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993 ; 43: 662-667.
47. Naismith RT and Cross AH Multiple sclerosis and black holes: connecting the pixels. Arch Neurol 2005 ; 62: 1666-1668.
48. Rovaris M., Comi G., Ladkani D., Wolinsky JS, Filippi M. and European/Canadian Glatiramer Acetate Study Group. Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2003 ; 24: 75-81.
49. Petkau J., Reingold SC, Held U., Cutter GR, Fleming TR, Hughes MD, Miller DH, McFarland HF and Wolinsky JS Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Mult Scler 2008 ; 14: 770-778.
50. Sormani MP, Bonzano L., Roccatagliata L., Cutter GR, Mancardi GL and Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009 ; 65: 268-275.
51. Daumer M., Neuhaus A., Morrissey S., Hintzen R. and Ebers GC MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009 ; 72: 705-711.
52. Noseworthy JH, Vandervoort MK, Wong CJ and Ebers GC Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology 1990 ; 40: 971-975.
53. Goodkin DE, Cookfair D., Wende K., Bourdette D., Pullicino P., Scherokman B. and Whitham R. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group. Neurology 1992 ; 42: 859-863.
54. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J., Syndulko K., Weinshenker BG, Antel JP, Confavreux C., Ellison GW, Lublin F., Miller AE, Rao SM, Reingold S., Thompson A. and Willoughby E. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999 ; 122 (Pt 5). 871-882.
55. Fischer JS, Rudick RA, Cutter GR and Reingold SC The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999 ; 5: 244-250.